Navigation Links
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
Date:4/8/2013

CAMBRIDGE, Mass., April 8, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel therapy MM-121 restores tumor sensitivity and delays the onset of resistance to the aromatase inhibitor, letrozole, in an ER+ breast cancer model. The study was presented as part of the American Association for Cancer Research's 2013 Annual Meeting in Washington, DC, April 6-10, 2013.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival. By inhibiting ErbB3 signaling, MM-121 was found to restore sensitivity, delay resistance and enhance the anti-tumor effect of letrozole as a combination therapy partner.

"In nearly all cases of advanced ER+ breast cancer, endocrine therapies are initially effective, but patients eventually develop resistance to these treatments," said Gavin MacBeath , Co-Founder and Head of Translational Research, Merrimack Pharmaceuticals. "We are excited to see that in preclinical models, MM-121 blocked activation of its target, ErbB3, and down-regulated several signaling pathways within these tumors.  We saw delayed resistance to letrozole when co-administered with the drug, and restored sensitivity when added after the tumors developed resistance to letrozole. These data help guide our thinking regarding how best to combine MM-121 with anti-hormonal therapies in the treatment of advanced ER+ breast cancer."

Study Methodology
The activity of MM-121 alone and in combination with letrozole was measured in an MCF7 in vivo model of post-menopausal ER+ breast cancer engineered to express aromatase. Models of ER+ breast cancer were randomized to receive letrozole, MM-121 or both MM-121 and letrozole following development of resistance to letrozole. Tumor
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
2. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
3. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
4. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
5. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
6. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
7. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
8. Valeant Pharmaceuticals Provides Update to Recent Event
9. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
10. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
11. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Victoria Vein & Surgery Clinic ... the Astanza Duality laser in Victoria, Texas ... as well as advanced laser treatments for a variety of ... tattoo industry to provide more services for their patients. Since ... many Victoria residents get rid of ...
(Date:3/27/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is celebrating a key milestone ... Complete Knee System. ,   ... first introduced the NexGen knee system, with its innovative design ... implantations of the NexGen knee have taken place worldwide. ... demonstrates the importance of design innovation and component quality for surgeons and ...
(Date:3/27/2015)... , March 27, 2015 Report ... for leading ophthalmic drug companies  What does ... pharma ophthalmic industry ? Visiongain,s brand new report shows ... and prospects there. Our 242-page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
... PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - ... 2 clinical,trial results for Hematide(TM) were presented ... in Barcelona, Spain by Iain C.,Macdougall, M.D., ... Macdougall's poster included data in previously-treated,dialysis patients ...
... also Showed Sustained Improvements in Blood Glucose,Control ... 23, 2007 /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and ... a study that showed BYETTA(R) (exenatide) injection,sustained ... weight,loss through three and a half years ...
Cached Medicine Technology:Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6
(Date:3/30/2015)... California (PRWEB) March 30, 2015 ... as radioactive isotopes, radiopharmaceuticals are used as tracers ... global market for radiopharmaceuticals is driven by the ... in the field of cardiology, neurology, pulmonology, and ... by the well-established use of radioisotopes in diagnostic ...
(Date:3/30/2015)... Daily sun exposure, stressors and environmental factors ... folds and other giveaways of age. However, advances in ... to hit the pause button, delaying the impact of ... or hack to rejuvenate any facial feature. , ... (AAFPRS) explores the intricacies of The Aging Face ...
(Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
(Date:3/30/2015)... 2015 BioFit Engineered ... manufacturer of ergonomic seating solutions, now offers ... new upholsteries bolster the company’s existing selection ... providing disinfectable, green choices. , The BioFit ... purveyor CF Stinson. Six disinfectable patterns consisting ...
(Date:3/29/2015)... 2015 At the 2015 International Health ... introduced the new Fonda wall mounted heater and ... Club owners and facilities managers with saunas smaller than ... design of the Fonda heater. With an attractive ... an immediate upgrade for a sauna, especially when mounted ...
Breaking Medicine News(10 mins):Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4Health News:New AAFPRS Infographic Addresses Concerns and Provides Aging Face Solutions 2Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:BioFit Adds Bleachable Upholstery Options to Seating Line 2Health News:Helo Commercial Introduces Fonda Sauna Heater and Sauna and Steam Continuing Education Program at IHRSA 2
... new and novel computer modeling platform developed through intensive, ... and cities to be more prepared for catastrophic public ... American Medical Association,s Disaster Medicine and Public Health ... to Multihazard Modeling and Simulation," is based on the ...
... Telemedicine, Mammography and Health Screenings on Wheels Expand Access ... June 11 Kaiser Permanente, one of America,s leading ... a new generation of mobile health. A first-of-its-kind, 500-sq-foot, ... home island of Hawaii, known to many as the ...
... off brain cell damage, lab study finds , THURSDAY, June ... may start with one protein that somehow goes astray and ... say. , Mad cow disease is considered a prion disease ... prion protein, or PrP, which normally is found on the ...
... is pleased to offer its stock alerts service to ... move and in the news can receive FREE Alerts by visiting ... , Today,s focused alerts include: Hemispherx Biopharma, Inc. (Amex: ... Cell Therapeutics, Inc. (Nasdaq: CTIC ), Cancer Therapeutics Inc. ...
... June 11 National figures, stars from the world of sports ... gathered today in Anaheim, California to celebrate 20 years of Drug ... reach of every American in need at the National Association of ... , Speaking in front of a crowd representing every U.S. state ...
... most common cancers in China. Although the association between ... studied, the relation between smoking, alcohol drinking, family history ... cancer still remains uncertain. So it is important to ... of sporadic colorectal cancer. A research team led ...
Cached Medicine News:Health News:A new computer modeling program can help hospitals prepare for the worst 2Health News:Kaiser Permanente Unveils the Nation's Most Wired Mobile Health Vehicle 2Health News:Kaiser Permanente Unveils the Nation's Most Wired Mobile Health Vehicle 3Health News:Protein Branded As Culprit in Mad Cow Disease 2Health News:GlobalEquityReport.com Issues Cancer Stocks On The Move Today: HEB, GNBT, CTIC, CTHP, DNDN 2Health News:U.S. Drug Czar Addresses 2,500 Drug Court Professionals, Voices Strong Support for Expanding Drug Courts Throughout the Nation 2Health News:U.S. Drug Czar Addresses 2,500 Drug Court Professionals, Voices Strong Support for Expanding Drug Courts Throughout the Nation 3
... Autostat™II Rheumatoid Factor IgM enzyme linked immunosorbent ... (RF IgM). Enzyme-linked immunosorbent assay method for ... Factor in human serum. The results of ... as an aid in the diagnosis of ...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
... GALILEI Dual Scheimpflug Analyzer is a high ... three dimensional analysis of the anterior eye ... Scheimpflug Camera and a Placido Disk. , ... Placido imaging furnishes high accuracy curvature data, ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: